摘要
目的:探讨平肝潜阳法对偏头痛肝阳上亢型大鼠模型治疗作用的分子机理。
方法:电刺激SD大鼠三叉神经节并灌服附子汤制造偏头痛肝阳上亢型模型。采用双向凝胶电泳(2-DE)技术分离大鼠肾上腺组织和脾脏淋巴细胞的总蛋白,图像分析识别差异表达的蛋白质点并鉴定蛋白质。
结果:1.模型组与正常对照组肾上腺总蛋白2-DE图像分析统计后发现模型组有9个蛋白质下调和5个蛋白质上调,经中药治疗后这些蛋白点的表达接近正常水平,得到了8个有意义的蛋白。
2.模型组与正常对照组脾脏淋巴细胞2-DE图像分析统计后发现模型组与正常对照组相比有16个蛋白质下调和4个蛋白质上调,经中药治疗后这些蛋白点的表达接近正常水平,其中鉴定到10个蛋白。
结论:1.平肝潜阳药物能改善偏头痛肝阳上亢型动物模型的头痛等相关症状。
2.偏头痛肝阳上亢型和中药治疗后的大鼠肾上腺组织和脾脏淋巴细胞差异蛋白质的表达呈动态变化。
3.膜联蛋白-A1、热休克蛋白-27和硫氧还蛋白过氧化物酶-Ⅱ可能与肝阳上亢证的形成有关。平肝潜阳药物可能通过调节体内的多种蛋白的表达而起到治疗偏头痛肝阳上亢证的作用。
Objective: To explore the molecule mechanisms of calming the liver and suppressing the hyperactive yang on migraine rat model with the hyperactivity of the liver-yang.
Methods: Rat animal model of migraine with hyperactivity of liver-yang was established through electrical trigeminal ganglion stimulation, and by administering orally with aconite decoction. The total proteins of adrenal gland and splenic lymphocytes in the rats were separated by immobilized pH gradient-based two-dimensional gel electrophoresis (2-DE), and the 2-DE images were analyzed by PDQuest 7.0 software. Searching in the database was used to identify the differential proteins.
Result: 1. There were 9 protein spots of adrenal glands expressing down-regulately and 5 up-regulately in the model group when compared to normal group. And they went back to normal lever in the therapy group. 8 differentially expressed proteins were identified.
2. There were 16 protein spots of splenic lymphocytes expressing down-regulately and 4 up-regulately in the model group when compared to normal group. And they went back to normal lever in the therapy group. 10 differentially expressed proteins were identified.
Conclusion: 1. Calming the liver and suppressing the hyperactive yang therapy can improve the headache of animals.
2. The differential proteins of adrenal gland and splenic lymphocytes in migraine rat model with the hyperactivity of the liver-yang and treated group had showed dynamic state.
3. Annexin-A1、Peroxirdoxin-II、Heat shock protein-27 were supposed to correlated with hyperactivity of the liver-yang. Calming the liver and suppressing the hyperactive yang therapy may effect on migraine with the hyperactivity of the liver-yang by accommodating the express of multitude proteins.
引文
[1]Scher AI,Stewart WF,Lipton RB.Migraine and headache:A meta-analytic approach.In:Crombie IK,ed.Epidemiology of Pain.Seattle,WA:IASP Press,1999:159-170.
[2]Lipton RB,Bigal ME,Diamond.Migraine prevalence,disease burden,and the need for preventive therapy.Neurology,2007,68:343-349.
[3]SilbersteinSD.Migraine.Lancet,2004,363:381-391.
[4]Vanmolkot KR,Kors EE,Hottenga JJ,et al.Novel mutations in the Na~+,K~+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions.Ann Neurol,2003,54:360-366.
[5]Kors EE,Vanmolkot KR,Haan J,et al.Recent findings in headache genetics.Curr Opin Neurol,2004,17:283-288.
[6]Wessman M,Kaunisto MA,Kallela M,et al.The molecular genetics of migraine.Ann Med,2004,36:462-473.
[7]Dichgans M,Freilinger T,Eckstein G,et al.Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine.Lancet,2005,366:371-377.
[8]Hadjikhani N,Sanchez delRio M,Wu O,et al.Mechanisms of migraine aura revealed by functional MRI in human visual cortex.Proc Natl Acad Sci USA,2001,98(8):4687-4692.
[9]Jianhua Qiu,Norihiro Matsuoka,Hayrunnisa Bolay,et al.Cortical spreading depression activates and upregulates MMP-9.The Journal of Clinical Investigation,2004,113(10):1447-1455.
[10]Fusco M,Andrea GD,MiccichéF,et al.Neurogenic inflammation in primary headaches.Neurol Sci,2003,24..S61-S64.
[11]Nagata E,Shibata M,Hamada J,et al.Plasma 5-hydroxytryptamine(5-HT)in migraine during an attack-free period.Headache,2006,46(4):592-596.
[12]王永久,刘坤,由振东.神经肽与偏头痛研究进展.国际神经病学神经外科学杂志,2006,33(2):157-159.
[13]Leonardi M,Steiner TJ,Scher AT.The global burden of migraine:measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health(ICF).J Headache Pain,2005,6(6):429-440.
[14]张树彪,王景阁.偏头痛的中西医治疗进展.天津中医学院学报,2006,25(1):55-56.
[15]Blackstock WP,Weir MP.Proteomics:quantitative and physical mapping of cellular proteins.TIB TECH,1999,17(3):121-127.
[16]李炜,钟广伟,王素娥,等.偏头痛大鼠脑干组织G蛋白亚基Gsa和Gia含量的变化.中国医师杂志,2004,6(4):493-494.
[17]鄢东红,金益强,肖纯,等.自发性高血压大鼠肝阳上亢证模型的复制.湖南中医学院学报,1999,19(4):35-38.
[18]Dimtriadou V,Buzzi MG,Moskowitz MA,et al.Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast calls.Neuroscience,1991,44(1):97-112.
[19]陈主初,梁宋平.肿瘤蛋白质组学.长沙:湖南科学技术出版社,2002:29-33.
[20]Goadsby PJ,Lipton RB,Ferrari MD.Migraine-current understanding and treatment.N Engl J Med,2002,346:257-270.
[21]Levy D,Jakubowski M,Burstein R.Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT_(1B/1D)receptor agonists.Proc Natl Acad Sci USA,2004,101:4274-4279.
[22]Moskowitz MA.Neurogenic inflammation in the pathophysiology and treatment of migraine.Neurology,1993,43:S16-S20.
[23]钟广伟,李炜,邓干初,等.针刺对偏头痛大鼠脑内降钙素基因相关肽基因表达的影响.中国临床康复,2002,6(24):3680-3681.
[24]钟广伟,李炜.偏头痛大鼠脑内5-羟色胺1F和诱导型一氧化氮合酶基因的表达变化及针刺的干预效应.中国组织工程研究与临床康复,2007,11(29):5761-5764.
[25]Dalkara T,Zervas NT,Moskowitz MA.From spreading depression to the trigeminovascular system.Neurol Sci,2006,27(Suppl2):S86-90.
[26]Johnson KW,Bolay H.Neurogenie inflammatory mechanisms.In:Olesen J,Goadsby PJ,Ramadan NM,et al.editors.The headaches,3rd edn.Philadelphia:Lipincott Williams & Wilkins,2006:309-319.
[27]Richardson JD,Vasko MR.Cellular mechanisms ofneurogenic inflammation.J Pharmacol Exp Ther,2002,302(3):839-845.
[28]金益强.中医肝脏象现代研究与临床.北京:人民卫生出版社,1999:154-155.
[29]陈国林,胡随瑜,陈泽奇,等.中医肝脏辨证标准规范化研究-肝阳上亢证辨 证标准.中国中医基础医学杂志,2001,7(12):13-16.
[30]金益强,胡随瑜,张翔,等.中医肝不同证候血浆去甲肾上腺素和肾上腺素含量及植物神经功能的研究.中国中西医结合杂志,1998,18(11):655-658.
[31]尤劲松,胡随瑜,夏大胜.肝阳上亢证辅助实验诊断指标的进一步研究.湖南医科大学学报,2002,27(3):239-241.
[32]宋炜熙,金益强,鄢东红,等.肝系不同证候血浆去甲肾上腺素和肾上腺素含量分析.山东中医药大学学报,2004,28(2):110-113.
[33]黎杏群,李学文,陈泽奇,等.中医肝病各证患者的血浆环核苷酸变化.湖南中医学院学报,2001,21(2):4-6.
[34]黎杏群,李学文,陈泽奇,等.中医肝病各证患者血浆血栓素B2和前列环素12水平研究.湖南中医学院学报,2001,21(4):9-11.
[35]杨卫平,王贵英.中药学.北京:中医古籍出版社,2002,262-273.
[36]李智,陈泽奇,李炜,等.偏头痛肝阳上亢证大鼠肾上腺蛋白质双向电泳图谱的分析.中国医学工程,2007,15(1):4-8.
[37]李智,李炜,陈泽奇,等.天麻钩藤饮对偏头痛肝阳上亢证大鼠下丘脑蛋白质的影响.中国临床康复,2006,10(47):45-48.
[38]陈孝银,肖蒲鲜,范隆昌.肝阳上亢者部分免疫指标变化的检测分析.四川中医,2000,18(3):7-8
[39]Sarchielli P,Alberti A,Baldi A,etc.Proinflammatory cytokines,adhesion molecules,and lymphocyte integrin Expression in the internal jugular blood of migraine patients without aura assessed ictally.Headache,2006,46(2):200-207.
[40]Schulz UG,Blamire AM,Corkill RG,et al.Association between cortical metabolite levels and clinical manifestations of migrainous aura:an MR-spectroscopy study.Brain,2007,130(12):3102-3110.
[41]Boska MD,Welch KMA,Barker PB,et al.Contrasts in cortical magnesium phospholipid and energy metabolism between migraine syndromes.Neurology,2002,58:1227-1233.
[42]Rozen TD,Oshinsky ML,Gebeline CA,et al.Open label trial ofcoenzyme Q10as a migraine preventive.Cephalalgia,2002,22:137-141.
[43]何伟珍,徐晓东.泛素-蛋白酶体途径与疾病冲国临床医药研究杂志,2006,152(7):64-66.
[44]谢映,梁清华,熊新贵,等.泛素羧基末端水解酶在肝阳化风证中的表达.实用预防医学,2007,14(2):270-272.
[45]Junker H,Suofu Y,Venz S,et al.Proteomic identification of an upregulated isoform of annexin A3 in the rat brain following reversible cerebral ischemia.Glia,2007,55(16):1630-1637.
[46]张立勇,赵晓航,吴旻.腊联蛋白I的结构和功能.生物化学与生物物理进展,2002,29(4):514-517.
[47]Evgrafov OV,Mersiyanova I,Irobi J,et al.Mutant small heat-shock protein 27causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy.Nat Genet,2004,36(6):602-606.
[48]Anastasios E,Damdimopoulos,Antonio Miranda-Vizuete,etc.Human Mitochondrial Thioredoxin involvement in mitochondrial membrane potential and cell death.J Biol Chem,2002,277(36):33249-33257.
[49]颜永平,易振佳,李炜,等.高血压大鼠肝阳上亢证的下丘脑双向凝胶电泳分析.中国医师杂志,2006,8(3):330-333.
[50]Pusch Michael,Accardit Alessio,Liantonlo Anton.Mechanisms of block of muscle type CLC chloride channels.Molecular membrane biology,2002,19(4):285-292.
[51]Pusch M.Structural insights into chloride and proton-mediated gating of ClC chloride channels.Biochemistry,2004,43:1135-1144.
[52]王冠蕾,关永源,王斌.氯通道阻断剂对T淋巴细胞增殖的影响.中国药理学通报,1999,15(2):146-149.
[53]Ricardo E,Dolmetsch Richard S,Lewis Christopher C,et al.Differential activation of transcription factors induced by Ca~(2+)response amplitude and duration.Nature,1997,386,855-858.
[54]Wing MR,Bourdon DM,Harden TK,et al.PLC-epsilon:a shared effector protein in Ras-,Rho-,and Gaβγ-mediated signaling.Mol Interv,2003,3:273-280.
[55]Lin H,Schlaepfer WW.Role of neurofilament aggregation in motor neuron disease.Ann Neurol,2006,60(4):399-406.
[56]潘琪,牛潮诗,程俊.蛋白酶体抑制剂诱导大鼠行为改变的研究.立体定向和功能性神经外科杂志,2007,20(3):129-132.
[1]Scher AI,Stewart WF,Lipton RB.Migraine and headache:A meta-analytic approach.In:Crombie IK,ed.Epidemiology of Pain.Seattle,WA:IASP Press,1999:159-170.
[2]Lipton RB,Bigal ME,Diamond.Migraine prevalence,disease burden,and the need for preventive therapy.Neurology,2007,68:343-349.
[3]Silberstein SD.Migraine.Lancet,2004,363:381-391.
[4]Leonardi M,Steiner TJ,Sober AT.The global burden of migraine:measuring disability in headache disorders with WHO's Classification of Functioning.J Headache Pain,2005,6(6):429-440.
[5] Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia, 2004, 24(Suppl.2): 2-7.
[6] Spierings ELH. Pathogenesis of the migraine attack. Clin J Pain, 2003, 19: 255-262.
[7] Villalon CM, Centurion D, Valdivia LF. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc, 2002, 45: 199-210.
[8] U Arulmani, JPC Heiligers, D Centurion, et al. Lack of effect of the adenosine A1 receptor agonist , GR79236 , on capsaicin-induced CGRP release in anaesthetized pigs. Cephalalgia, 2005, 25(11): 1082-1090.
[9] De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol, 1999, 375: 61-74.
[10] Saxena PR. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models, Vol.27.Philadelphia: Lippincott-Raven Publishers, 1995, 189-198.
[11] Den Boer MO, Van Woerkens LJ, Somers JA, et al. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol, 1993, 75: 782-789.
[12]Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia, 2004, 24: 611-622.
[13]Tom B, De Vries P, Heiligers JP, et al. Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs. Cephalalgia, 2002, 22: 37-47.
[14]Villalon CM, Centurion D, Willems EW, et al. 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol, 2004, 484: 287-290.
[15] Villalon CM, Sanchez-Lopez A, Centurion D. Operational characteristics of the 5-HT1-like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Close resemblance to the 5-HT1D receptor subtype. Naunyn Schmiedebergs Arch Pharmacol, 1996, 354: 550-556.
[16]De Vries P, Sanchez-Lopez A, Centurion D, et al. The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists. Eur J Pharmacol, 1998, 362: 69-72.
[17]Silberstein SD,McCrory DC.Ergotamine and dihydroergotamine:history,pharmacology,and efficacy.Headache,2003,43:144-166.
[18]Willems EW,Valdivia LF,Ramirez-San Juan E,et al.Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline.Life Sci,2001,69:143-153.
[19]Willems EW,Valdivia LF,Villal6n CM,et al,Possible role of alpha-adrenoceptor subtypes in acute migraine therapy.Cephalalgia,2003,23:245-257.
[20]Read SJ,Smith MI,Hunter AJ,et al,Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat.Cephalalgia.1997,17(3):159-165.
[21]Offenhauser N,Zinck T,Hoffmann J,et al,CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion.Cephalalgia,2005,25(3):225-236.
[22]Arpad K.Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis.Neuroreport,2000,14(28):3071-3075.
[23]Hoskin KL,Goadsby PJ.Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME.Neuroscience letters,1999,266(3):173-176.
[24]Aoki KR.Evidence for antinociceptive activity of botulinum toxin type A in pain management.Headache,2003,43(Suppl 1):S9-S15.
[25]彭成,任永欣,姚干,等.实验性偏头痛动物模型C-fos,C-jun基因表达.中国实验动物学报,2000,8(2):112-119.
[26]Christiansen I,Thomsen LL,Daugaard D,et al.Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.Cephalalgia,1999,19(7):660-667.
[27]Tvedskov JF,Thomsen LL,Thomsen LL,et al.The effect of propranolol on glyceryltrinitrate-induced headache and arterial response.Cephalalgia,2004,24(12):1076-1087.
[28]Lassen LH,Sperling B,Andersen AR,et al.The effect of i.v.L-NG methylarginine hydrochloride(L-NMMA:546C88)on basal and acetazolamide induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man.Cephalalgia,2005,25(5):344-352.
[29]Srikiatkhachom A,Anuntasethakul T,Phansuwan-Pujito P,et al.Effect of serotonin depletion on nitric oxide induced cerebrovascular nociceptive response.Neuroreport,2001,12(5):967-971.
[30]邓凤军,陈锡林.实验性偏头痛小鼠造模方法探讨.中华现代临床医学杂志,2005,3(8):708-710.
[31]杜力军,孙虹.精制吴茱萸胶囊对偏头痛小鼠的作用.中药药理与临床,1999,15(3):3-5.
[32]Goadsby PJ,Lipton RB,Ferrari MD.Migraine--current understanding and treatment.N Engl J Med,2002,346:257-270.
[33]Levy D,Jakubowski M,Burstein R.Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT_(1B/1D)receptor agonists.Proc Natl Aead Sci USA,2004,101:4274-4279.
[34]Moskowitz MA.Neurogenic inflammation in the pathophysiology and treatment of migraine.Neurology,1993,43:S16-S20.
[35]Goldstein DJ,Roon KI,Often WW,et al.Selective serotonin 1F(5-HT1F)receptor agonist LY334370 for acute migraine:a randomised controlled trial.Lancet,2001,358:1230-1234.
[36]Cutrer FM,Yu XJ,Ayata G,et al.Effects of PNU-109 291,a selective 5-HT1D receptor agonist,on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis.Neuropharmacology,1999,38:1043-1053.
[37]Cutrer FM,O'Donnell A,Sanchez del Rio M.Functional neuroimaging:enhanced understanding of migraine pathophysiology.Neurology,2000,55:S36-S45.
[38]Brandli P,Loftier BM,Breu V,et al.Role of endothelin in mediating neurogenie plasma extravasation in rat dura mater.Pain,1996,64:315-322.
[39]May A,Shepheard SL,Knorr M,et al.Retinal plasma extravasation in animals but not in humans:implications for the pathophysiology of migraine.Brain,1998,121:1231-1237.
[40]陈磊,王怀良,邢军,等.植物药生物碱94-95-10L对大鼠CSD模型脑内c-fos基因表达.中国医科大学学报,2000,29(3):172-174.
[41]Maneesri S,Patamanont J,Patumraj S,et al.Cortical spreading depression,meningeal inflammation and trigeminal nociception.Neuro report,2004,15(10):1623-1627.
[42]李鹏程,陈尚宾,骆卫华,等.大鼠皮层扩散性抑制过程的在体内源光信号成 像.生物化学与生物物理进展,2003,30(4):605-611.
[43]Bolay H,Reuter U,Dunn AK,et al.Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.Nature Med,2002,8:136-142.
[44]Moskowitz MA.Basic mechanisms in vascular headache.Neurol Clin,1990,8:801-815.
[45]Lauriczen MJ,Orgensen MB,Diemer NH,et al.Persistent oligemia of rat cerebral cortex in the wake of spreading depression.Ann Neurol,1982,12:469-474.
[46]Jianhua Qiu,Norihiro Matsuoka,Hayrunnisa Bolay,et al.Cortical spreading depression activates and upregulates MMP-9.The Journal of Clinical Investigation,2004,113(10):1447-1455.
[47]Bartsch T,Goadsby PJ.Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input.Brain,2002,125:1496-1509.
[48]Aurora SK,Ahmad BK,Welch KMA,et al.Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine.Neurology,1998,50:1111-1114.
[49]Ophoff RA,Terwindt GM,Vergouwe MN,et al.Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca~(2+)channel gene CACNA1A.Cell,1996,87:543-552.
[50]Vanmolkot KR,Kors EE,Hottenga JJ,et al.Novel mutations in the Na~+,K~+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions.Ann Neurol,2003,54:360-366.
[51]Kors EE,Vanmolkot KR,Haan J,et al.Recent findings in headache genetics.Curr Opin Neurol,2004,17:283-288.
[52]Wessman M,Kaunisto MA,Kallela M,et al.The molecular genetics of migraine.Ann Med,2004,36:462-473.
[53]Dichgans M,Freilinger T,Eckstein G,et al.Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine.Lancet,2005,366:371-377.
[54]Van den Maagdenberg AM,Pietrobon D,Pizzorusso T,et al.A CACNA1A knockin migraine mouse model with increased susceptibility to cortical spreading depression.Neuron,2004,41:701-710.
[1]Dalkara T,Zervas NT,Moskowitz MA.From spreading depression to the trigeminovascular system.Neurol Sci,2006,27(Suppl 2):S86-90.
[2]Johnson KW,Bolay H.Neurogenic inflammatory mechanisms.In:Olesen J,Goadsby PJ,Ramadan NM,et al.editors.The headaches,3rd edn.Philadelphia:Lipincott Williams & Wilkins,2006:309-319.
[3]Richardson JD,Vasko MR.Cellular mechanisms of neurogenic inflammation.J Pharmacol Exp Ther,2002,302(3):839-845.
[4]Goadsby PJ,Edvinssonl L,Ekman R.Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.Ann Neurol,1990,28(2):183-187.
[5]Juhasz G,Zsombok T,Gonda X,et al.Nitroglycerin-induced headaches.Orv Hetil,2004,145(46):2323-2328.
[6]Lassen LH,Haderslev PA,Jacobsen VB,et al.CGRP may play a causative role in migraine.Cephalalgia,2002,22(1):54-61.
[7]Juhasz G,Zsomok T,Jakab B,et al.Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide(CGRP)concentration and migraine headache during nitroglycerin induced migraine attack.Cephalalgia,2005,25(3):179-183.
[8]Bellamy JL,Cady RK,Durham PL,et al.Salivary Levels of CGRP and VIP in Rhinosinusifis and Migraine Patients.Headache:J Head Face Pain,2006,46:24-33.
[9]Brain SD.Calcitonin gene-related peptide(CGRP)antagonists:blockers of neuronal transmission in migraine.Br J Pharmacol,2004,142(7):1053-1054.
[10]Akerman S,Williamson DJ,Kaube H,et al.Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin generelated peptide induced dilation of dural meningeal vessels.Br J Pharmacol,2002,137(1):62-68.
[11]Storer RJ,Akerman S,Goadsby PJ,et al.Calcitonin gene-related peptide(CGRP)modulates nociceptive trigeminovascular transmission in the cat.Br J Pharmacol,2004,142(5):1171-1181.
[12]Olesen J,Diener HC,Husstedt IW,et al.Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine.N Engl J Med,2004,350(11):1104-1110.
[13]Freitag FG,Diamond S,Diamond M,et al.Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.Headache,2008,48(2):201-209.
[14]Samsam M,Covenas R,Ahangari R,et al.Simultaneous depletion of neurokinin A,substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion.Pain,2000,84(2-3):389-395.
[15]Asakura K,Kanemasa T,Minagawa K,et al.alpha-Eudesmol,aP/Q-type Ca~(2+)channel blocker,inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion.Brain Res,2000,873(1):94-101.
[16]May A,Goadsby PJ.Substance P receptor antagonists in the therapy of migraine.Expert Opin Investig Drugs,2001,10(4):673-678.
[17]姜波,李清美,于素清,等.女性偏头痛患者血浆中β-内啡肽和P物质含量的定量分析.中华神经科杂志,1999,32(1):60-62.
[18]Diener HC.RPR100893,a substance-P antagonist,is not effective in the treatment of migraine attacks.Cephalalgia,2003,23(3):183-185.
[19]Hill R.NK1(substance P)receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci,2000,21:244-246.
[20]Barbanti P,Fabbrini G,Pesare M,et al.unilateral cranial autonomic symptoms in migraine. Cephalalgia, 2002, 22 (4): 256-259.
[21]Tajti L Uddman R, Edvinsson L. Neuropeptide localization in the 'migraine generator' region of the human brainstem. Cephalalgia, 2001, 21 (2): 96-101.
[22]Hu ZQ, Song LG, Mei T. Clinical and experimental study on treatment of migraine with shutianning granule. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2002, 22(8): 581-583.
[23]Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol, 1998, 30(3): 293-298.
[24]Marek A, Brodzicki J, Liberek A, et al. TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions-a new diagnostic and prognostic marker? Med Sci Monit, 2002, 8(7): RA145-RA151.
[25]Rollnik JD, Sindern E, Schweppe C, et al. Biologically active TGF-beta 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand, 1997, 96(2): 101-105.
[26]Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology, 2000, 55(5): 624-629.
[27]Ishizaki K, Takeshima T,Fukuhara Y, et al. Increased plasma transforming growth factor-beta-1 in migraine. Headache, 2005, 45(9): 1224-1228.
[28]Inoue K, Yamazaki H, Manabe Y, et al. Transforming growth factor-beta activated during exercise in brain depresses spontaneous motor activity of animals Relevance to central fatigue. Brain Res, 1999, 846(2): 145-153.
[29]Paola Sarchielli, Andrea Alberti, Luana Vaianella, et al. Chemokine Levels in the Jugular Venous Blood of Migraine Without Aura Patients During Attacks. Headache, 2004, 44(10), 961-968.
[30]Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain, 2001, 124: 2490-2502.
[31] Munno I, Marinaro M, Bassi A, et al. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache, 2001, 41(8): 764-767.
[32]Hashimoto M, Yamamoto Y, Takagi H. Effects of KB-2796 on plasma extravasation following antidromic trigeminal stimulation in the rat. Res Commun Mol Pathologic Pharmacol, 1997, 97(1): 79-94.
[33]Gazerani P, Pourpak Z, Ahmadiani A, et al. A Correlation between Migraine, Histamine and Immunoglobulin E. Iran J Allergy Asthma Immunol, 2003, 2(1): 17-24.
[34]Thomsen LL. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia, 1997, 17(8): 873-895.
[35]Millan Guerrero R, Trujillo Herndndez B, Tene CE, et al. Subcutaneous histamine in migraine prophylaxis Initial effects and long-term outcome. Neurologia, 2006, 21(2): 55-59.
[36]Milldn-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous Histamine versus Topiramate in Migraine Prophylaxis: A Double-Blind Study. Eur Neurol, 2008, 8, 59(5): 237-242.
[37]Umberto P, Massimo DL, Enrico DB. Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura. Current Therapeutic Research, 2004, 65(1): 70-78.
[38] Sanchez-del-Rio M, Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol, 2004, 17(3): 289-293.
[39]Zeller JA, Frahm K, Baron R, et al. Platelet-leukocyte interaction and platelet activation in migraine: A link to ischemic stroke. J Neurol Neurosurg Psychiatry, 2004, 75(7): 984-987.
[40]Ebersberger HG, Schaible, Averbeck B, et al. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol, 2001, 49 (1): 7-13.
[41]BolayH, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med, 2002, 8: 136-142.
[42]Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain, 2002, 125: 102-112.
[43]Goadsby PJ. The pharmacology of headache. Prog Neurobiol, 2000, 62(5): 509-525.
[44]Nagata E, Shibata M, Hamada J, et al. Plasma 5-hydroxytryptamine (5-HT) in migraine during an attack-free period. Headache, 2006, 46(4): 592-596.
[45]Kanazawa F, Nakanishi K, Osada H, et al. Expression of endothelin-1 in the brain and lung of rats exposed to permanent hypobaric hypoxia. Brain Res, 2005, 1036(1-2): 145-154.
[46] Schilling L, Feger GI, EhrenreichH, et al. Endothelin-1-induced contraction and relaxation of isolated rat basilar artery: effect of the endothelium. J Cardiovasc Pharmacol, 1995, 26(3): S197-S199
[47]May A, Gijsman HJ, Wallnofer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain, 1996, 67: 375-378.
[48]Hasselblatt M, Kohler J, Voiles E, et al. Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport, 1999, 10(4): 423-425.
[49]Cutrer FM, Moskowitz MA, Wolff. Award 1996: The actions of valproate and neurosteroids in a model of trigeminal pain. Headache, 1996, 36(10): 579-585.
[50]Storer RJ, Akerman S, Shields KG, et al. GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. Brain Res, 2004, 1013: 188-193.
[51]Russo L, Mariotti P, Sangiorgi E, et al. A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am J Hum Genet, 2005, 76(2): 327-333.
[52]Schindler M,Holloway S,Hathway G, et al. Identification of somatostatin SST2(a) receptor expressing neurones in central regions involved in nociception. Brain Res, 1998, 798: 25-35.
[53]Sarchielli P, Alberti A, Candeliere A, et al. Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia, 2006, 26: 409-415.
[54]Pawlak M, Meβlinger K, Zehnter A, et al. Somatostatin reduces the meningeal arterial blood flow in the rat. Neuroscience Letters, 1999, 276(1): 33-36.
[55]Goadsby PJ. New targets in the acute treatment of headache. Curr Opin Neurol, 2005, 15: 283-288.
[56]Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol, 2000, 47(2): 238-241.
[57]Herbert MK, Holzer P. Neurogenic inflammation II pathophysiology and clinical implications. Anasthesiol Intensivmed Notfallmed Schmerzther, 2002, 37(7): 386-394.
[58] May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine. Brain, 1998, 121(7): 1231-1237.
